Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age greater than or equal to 18 years
Histologically confirmed NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma).
Unresectable Stage IIIB with pleural effusion or stage IV NSCLC
ECOG performance status of 0 or 1
You may not be if
Patients who received an IV bisphosphonate (e.g.pamidronate; zoledronic acid)
Patients who received an oral bisphosphonate therapy in the 6 months prior to screening (alendronate; etidronate; risedronate; tiludronate; ibandronate)
Patients who are currently receiving any investigational drugs that are suspected to have renal toxicity and/or are excreted by the kidneys
Known clinically significant hypersensitivity to zoledronic acid or other bisphosphonates or any of the excipients in the formulation of zoledronic acid (mannitol, sodium citrate)
Abnormal renal function or creatinine clearance
Unstable brain metastasis
Women of childbearing potential not using a medically recognized form of contraception, as well as women who are breastfeeding
Patients with nonmalignant conditions which would confound the evaluation of the primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol
